Case Report

Diffuse Universal Hyperpigmentation Induced by Imatinib Mesylate

  • Sudip Kumar Ghosh
  • Debabrata Bandyopadhyay
  • Gobinda Chatterjee
  • Arghyaprasun Ghosh

J Turk Acad Dermatol 2008;2(1):0-0


Imatinib mesylate, a tyrosine kinase inhibitor, is increasingly being used in the treatment of chronic myeloid leukemia and other oncological disorders. It may cause a large number of cutaneous adverse effects. We are reporting here a case of diffuse universal hyperpigmentation following imatinib therapy, showing lichenoid interface dermatitis on histopathology, a hitherto unreported entity.

Keywords: universal hyperpigmentation, imatinib mesylate